Joinstar SARS-CoV-2 Neutralizing Antibody Rapid Test (Fluorescence Dry Quantitative Immunoassay) was officially sold in foreign markets

Recently, SARS-CoV-2 Neutralizing Antibody Rapid Test (Fluorescence Dry Quantitative Immunoassay) developed by Joinstar Biomedical Technology Co., Ltd. and Nanshan Pharmaceutical Research Institute of Guangdong province was officially sold to overseas markets. The kit is a quantitative immunoassay based on membrane chromatography for the detection of SARS-CoV-2 neutralizing antibodies in human serum, plasma or whole blood. It can be used clinically to evaluate neutralizing antibodies in COVID-19 rehabilitative patients after infection or to assist in evaluating the effect of COVID-19 vaccine.

The SARS-CoV-2 Neutralizing Antibody Rapid Test (Fluorescence Dry Quantitative Immunoassay) are tested on FIC-Q100 Dry Fluorescence Immunoassay Analyzer. It only requires 20μL serum, plasma or whole blood (fingertip blood can be used) sample to perform the test. The test around time is 10 minutes, and the quantitative analysis is carried out by the analyzer, and the inhibition rate of neutralizing antibody is directly displayed.

The kit has provided all components required for operation. It can be tested with FIC-Q100 Dry Fluorescence Immunoassay Analyzer without using other consumables. It is suitable for large, medium and small medical institutions. In addition, the kit does not need cold chain transportation--In a sealed environment of 2 ℃ ~ 30 ℃, the validity period is 12 months. It is very convenient for transportation and storage.

SARS-CoV-2 Neutralizing Antibody

Coronavirus disease 2019 (COVID-19) is a highly infectious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 belongs to the subfamily of β-coronaviruses that infect humans and may cause severe disease and lead to death. It has several structural proteins including nucleocapsid protein (N), membrane protein(M), envelope protein (E) and spike glycoprotein (S). Cell entry of SARS-CoV-2 depends on binding of the viral S protein, which is composed of S1 and S2 subunits. S1 subunit mediates the binding of virus to host cell surface receptor, and S2 subunit is responsible for the fusion of virus and cell.

S1 subunit contains an N-terminal domain (NTD) and a receptor binding domain (RBD). It was found that RBD interacted strongly with human angiotensin converting enzyme 2 (ACE2) receptors on the surface of human cells, resulting in endocytosis into the host cells of the deep lung and viral replication. Infection with SARS-CoV-2 initiates immune responses, which include the production of neutralizing antibodies in the blood. Such antibodies provide protection against future infections from viruses, because they remain in the circulatory system for months to years after infection and will bind quickly and strongly to the pathogen to block cellular infiltration and replication.  

The SARS-CoV-2 neutralizing antibody mainly interacts with RBD to block the binding of S protein to ACE2 on the host cell surface, thereby preventing the virus from entering the host cell. With the popularity of SARS-CoV-2 vaccination worldwide, the effectiveness of vaccination has attracted much attention. The detection of SARS-CoV-2 neutralizing antibodies is increasingly recognized by experts. 

Contact：

Stanley Shen/International business manager

Tel: + 86-13957167265

+86-571-89023160

Email:info@joinstar.cn

Web: en.joinstar.cn